RxDoctor Payments Data

Robert King, MD

Ophthalmology · Savannah, GANPI 1952340408

Payments from drug & device makers

What this record shows

This record is dominated by ownership interests: $5,461 of the $7,028 with a category attached, or 77.7%. US Retina LLC accounts for 79.4% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2022 at $2,654 and has fallen 94.2% since, to $155 in 2025.

$7,028in general payments, 2019–2025

Across 68 payments — averaging $103.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • US Retina LLC$6K
  • Regeneron Healthcare Solutions, Inc.$704
  • Genentech USA, Inc.$532
  • Novartis$82
  • Eyepoint US, Inc.$35
  • Shire North American Group Inc$31
  • plus $62 from 3 others
$38,663in ownership & investment interests, 2019–2025

Across 7 payments — averaging $5523.29 each. An ownership or investment interest held by the physician or an immediate family member.

  • Stimlabs LLC$39K
  • US Retina LLC$0

What the payments were for

  • Food & beverage$1,56722%
  • Ownership interest$5,46178%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,028 in reported general payments places this provider in the 80th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$4,598,107
Medicare patients
1,210
Services billed
19,956

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Alphagan PBrimonidine Tartrate29$5,671
CombiganBrimonidine Tartrate/Timolol18$4,807
Prednisolone Acetate101$4,067
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol38$3,671
Timolol Maleate89$3,423
Latanoprost210$2,480
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha104$1,264
Brimonidine Tartrate47$1,072
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat76$1,068
Diclofenac Sodium15$173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieAlphagan P, Combigan$24$10,47847 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →